Nanobiotechnological approaches for breast cancer Management: Drug delivery systems and 3D In-Vitro models

Basit Öğe Kaydı
dc.contributor.authorAbolhassani, Hossein
dc.contributor.authorEskandari, Alireza
dc.contributor.authorPoor, Anita Saremi
dc.contributor.authorZarrabi, Ali
dc.contributor.authorKhodadadi, Behnoosh
dc.contributor.authorKarimifard, Sara
dc.contributor.authorSahrayi, Hamidreza
dc.date.accessioned2024-05-19T14:45:56Z
dc.date.available2024-05-19T14:45:56Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractThe science of nanotechnology has been proposed as a factor of main change in the field of cancer diagnosis and treatment. The challenges in common clinical treatment of breast cancer can be dominate by proof targeting of cancer cells by nanoscale drug delivery system. Due to specific properties of nanoparticles such as biocompatibility, minimum toxicity, excellent stability, multifunctional encapsulations of therapeutic agents, increased in permeability and retention effect, selective and proof targeting, they can apply for cancer therapy. Multidrug resistance to many of chemotherapy drugs is one of the main challenges in conventional chemotherapy that can be overcome by nanoparticles. However, in vivo and in vitro studies is limited in this field, and the number of approved nano formulation drugs has not increased significantly over the years. Successful clinical translation of nanomedicines is arduous requiring considerable preclinical tests. Two-dimensional (2D) monolayer cell cultures and in vivo animal models, which are routinely used for cancer research and drug discovery/screening seem inadequate. To address this challenge, biomimetic in vitro three-dimensional (3D) tumor models like spheroids, organoids, scaffolds/hydrogels, bioprinted, and microfluidic chips have been established using the breast tumor engineering approach. Taking the physiopathology of the breast cancer microenvironment into account, such models have the potential to enhance disease modeling and preclinical drug/nanomedicine screening. The development of 3D cancer models comprised of the patient's own cancer, stromal, and immune cells can be exploited as a promising preclinical platform and provide personalized cancer therapy.en_US
dc.identifier.doi10.1016/j.ccr.2024.215754
dc.identifier.issn0010-8545
dc.identifier.issn1873-3840
dc.identifier.scopus2-s2.0-85188147796en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org10.1016/j.ccr.2024.215754
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5398
dc.identifier.volume508en_US
dc.identifier.wosWOS:001206681300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Science Saen_US
dc.relation.ispartofCoordination Chemistry Reviewsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectNanocarrieren_US
dc.subjectDrug Deliveryen_US
dc.subjectTumor Targetingen_US
dc.subjectDisease Modelingen_US
dc.subject3d Cell Cultureen_US
dc.subjectTumor Spheroidsen_US
dc.subjectMicrofluidicsen_US
dc.titleNanobiotechnological approaches for breast cancer Management: Drug delivery systems and 3D In-Vitro modelsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu